Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma
Information source: Sunovion
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI (Drug); Racemic Albuterol followed by levalbuterol HFA MDI (Drug)
Phase: Phase 2
Sponsored by: Sunovion
The purpose of this study is to compare the safety and tolerability of levalbuterol HFA
metered dose inhaler (MDI) versus racemic albuterol HFA MDI in pediatric subjects 4-11 years
of age with asthma
Official title: A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatric Subjects With Asthma
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Increases from visit pre-dose to each post-dose dose measurement in heart rate, blood pressure (systolic and diastolic), potassium and glucose
Percent change in FEV1 (from visit pre-dose to each post dose measure)
Percent change in FVC (from visit pre-dose to each post dose measure)
Percent change in FEF25-75% (from visit pre-dose to each post dose measure)
Number of cumulative actuations received
A randomized, double-blind, active-controlled multicenter, two-way crossover study of HFA
levalbuterol (with and without a spacer) in subjects 4-11 years of age with asthma. This
study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by
Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
Minimum age: 4 Years.
Maximum age: 11 Years.
- Subject, male or female, must be between the ages of 4 to 11 years, inclusive, at the
time of consent.
- Female subjects who are 8 years of age or older will have a negative serum pregnancy
test at study start.
- Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to
- Subject must be in good health with the exception of their reversible airways disease
and not suffering from any chronic condition that might affect their respiratory
- Subject must have a chest X-ray or have one taken within 12 months prior to
randomization may be used.
- Subject's parent/legal guardian must be able to complete the diary cards and medical
event calendars reliably on a daily basis and understand dosing instructions. Any
subject who is not able to do this must have a parent/legal guardian who can assist
them during the study with these activities.
- Female subject who is pregnant or lactating.
- Subject who has participated in an investigational drug study within 30 days prior to
study start, or who is currently participating in another clinical trial.
- Subject whose schedule prevents him or her from taking the first daily dose of study
medication and/or starting study visits before 9 AM.
- Subject who has travel commitments during the study that would interfere with trial
measurements or compliance or both.
- Subject who has a history of hospitalization for asthma within 4 weeks prior to study
start, or who is scheduled for in-patient hospitalization, including elective surgery
during the course of the trial
- Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the
excipients contained in any of these formulations.
- Subject using any prescription drug with which albuterol sulfate administration is
- Subject with currently diagnosed life-threatening asthma defined as a history of
asthma episodes requiring intubation, associated with hypercapnia, respiratory
arrest, or hypoxic seizures within 3 months prior to study start.
- Subject with a history of cancer.
- Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure
- Subject with a history of substance abuse or drug abuse within 12 months preceding
- Subject with a history of cigarette smoking or use of any tobacco products.
- Subject with a documented history of bronchopulmonary aspergillosis or any form of
- Subject who has suffered from a clinically significant upper or lower respiratory
tract infection in the 2 weeks prior to study start.
- Subject with unstable asthma; or who have had a change in asthma therapy; or a visit
to the Emergency Department or hospital for worsening asthma within 4 weeks.
- Subject who is a staff member or relative of a staff member.
Locations and Contacts
Madera, California, United States
San Diego, California, United States
Savannah, Georgia, United States
Louisville, Kentucky, United States
Cortland, New York, United States
Medford, Oregon, United States
Portland, Oregon, United States
Chester, Pennsylvania, United States
Knoxville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Starting date: January 2003
Last updated: February 21, 2012